相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER plus Advanced Breast Cancer
Ben O'Leary et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
Marzia Del Re et al.
PHARMACOLOGICAL RESEARCH (2021)
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
Ryohei Ogata et al.
BREAST CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
Olga Martinez-Saez et al.
NPJ BREAST CANCER (2021)
A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice
Matthew W. Boudreau et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
Lauren Darrigues et al.
BREAST CANCER RESEARCH (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa et al.
CANCER DISCOVERY (2020)
GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models
Shanchun Guo et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Amelia McCartney et al.
CLINICAL CANCER RESEARCH (2020)
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Elaine Kilgour et al.
CANCER CELL (2020)
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi et al.
ONCOGENE (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Challenges and achievements of liquid biopsy technologies employed in early breast cancer
Alfonso Alba-Bernal et al.
EBIOMEDICINE (2020)
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey et al.
CANCERS (2020)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Neil A. O'Brien et al.
BREAST CANCER RESEARCH (2020)
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer (vol 77, pg 2488, 2017)
Valerie M. Jansen et al.
CANCER RESEARCH (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell et al.
CELL REPORTS (2019)
Efficacy of abemaciclib (abema) after palbociclib (palbo) in patients (pts) with metastatic breast cancer (MBC).
Veronica Mariotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
Seth Andrew Wander et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic markers of early progression on fulvestrant with or without palbociclib for ER plus advanced breast cancer in the PALOMA-3 trial.
Ben O'Leary et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients
Marzia Del Re et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
M. Brandao et al.
ANNALS OF ONCOLOGY (2019)
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Xueqian Gong et al.
CANCER DISCOVERY (2019)
Everolimus Reverses Palbociclib Resistance in ER plus Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
Lin Chen et al.
MEDICAL SCIENCE MONITOR (2019)
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W. Lok et al.
CANCER DISCOVERY (2019)
Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors
Claire R. Hall et al.
CANCER RESEARCH (2019)
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M. Hyman et al.
JCO PRECISION ONCOLOGY (2019)
Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study
P. Neven et al.
CANCER RESEARCH (2019)
Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
C. Guarducci et al.
CANCER RESEARCH (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer
P Mao et al.
CANCER RESEARCH (2018)
Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
Ajay Dhakal et al.
CLINICAL BREAST CANCER (2018)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
Martina Bonechi et al.
Oncotarget (2018)
Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker
Kiran Kumar Jagarlamudi et al.
BIOMARKERS IN MEDICINE (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
F André et al.
ANNALS OF ONCOLOGY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
Rekha Gyanchandani et al.
ONCOTARGET (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Aurora kinases: novel therapy targets in cancers
Anqun Tang et al.
ONCOTARGET (2017)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer
Carla L. Alves et al.
CLINICAL CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer?
Lesley-Ann Martin et al.
CANCER CELL (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
C. Elizabeth Caldon et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Todd W. Miller et al.
BREAST CANCER RESEARCH (2011)
Loss of pRB causes centromere dysfunction and chromosomal instability
Amity L. Manning et al.
GENES & DEVELOPMENT (2010)
Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase
Zhiyong Ding et al.
PLOS ONE (2010)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression
SM Keenan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
